1. Thiotepa intrathecal injections for myelomatous central nervous system involvement.
- Author
-
Claudel, Alexis, Talbot, Alexis, Harel, Stéphanie, Royer, Bruno, Naelle, Lombion, Zagdanski, Anne‐Marie, Madelaine, Isabelle, Lemaire, Pierre, and Arnulf, Bertrand
- Subjects
CENTRAL nervous system ,INTRATHECAL injections ,MENINGEAL cancer - Abstract
After relapse or progression of the CNS-MM disease, four of the 13 (31%) patients continued to receive second-line therapy for CNS-MM and one of 13 (8%) a third-line therapy. Keywords: multiple myeloma; central nervous system; extramedullary disease; intrathecal injections; thiotepa EN multiple myeloma central nervous system extramedullary disease intrathecal injections thiotepa e9 e12 4 04/19/21 20210415 NES 210415 The worldwide incidence of multiple myeloma (MM) has been rising continuously, representing an overall increase of 126% from 1990 to 2016 in almost all regions, regardless of socio-demographic status and availability of sensitive diagnostic techniques.1 Though remarkable progress has been made, the disease is still currently incurable. Emergence of central nervous system myeloma in the era of novel agents: CNS myeloma. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF